Assessing Clinical Utility of Datopotamab Deruxtecan Versus Chemotherapy for Breast Cancer

Xuan Wang

Ethan B. Ludmir

Noah S. Meimoun, BA, Division of Radiation Oncology, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; Alexander D. Sherry, MD, Department of Radiation Oncology, The Mayo Clinic, Rochester, MN; Ethan B. Ludmir, MD, Division of Radiation Oncology, Department of Gastrointestinal Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; and Timothy A. Lin, MD, MBA, Division of Radiation Oncology, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Lee-Jen Wei

Xuan Wang, PhD, Department of Population Health Sciences, University of Utah, Salt Lake City, UT; Ethan B. Ludmir, MD, Department of Gastrointestinal Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; and Lee-Jen Wei, PhD, Department of Biostatistics, Harvard University, Boston, MA